Biogen (BIIB) Tops Q1 EPS by 6c; cuts guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $214.94 +2.00%
EPS Growth %: -57.8%
Financial Fact:
Restructuring charge: 11.6M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -57.8%
Financial Fact:
Restructuring charge: 11.6M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q1 EPS of $3.02, $0.06 better than the analyst estimate of $2.96. Revenue for the quarter came in at $2.43 billion versus the consensus estimate of $2.23 billion.
GUIDANCE:
Biogen sees FY2025 EPS of $14.50-$15.50, versus the consensus of $15.20.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle reports earnings today: AI spending bet faces its toughest test yet
- AeroVironment (AVAV) Tops Q1 EPS by 29c, Offers Guidance
- DA Davidson Reiterates Buy Rating on EVI Industries Inc. (EVI) Following Q4 Results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
